RYTHMOIRESEARCH
SMS Research Updates ↗

SYK / Healthcare

STRYKER CORP

Surgical & Medical Instruments & Apparatus

Company overview

STRYKER CORP is an SEC-reporting issuer listed on NYSE under SYK. Its SEC industry description is Surgical & Medical Instruments & Apparatus. This profile organizes annual financial disclosures for research; sector labels are editorial groupings, not GICS classifications.

Drug developers, device manufacturers and care providers depend on distinct clinical, reimbursement and operating economics.

Business segments

Segment-level revenue is not included in this standardized dataset. Consult the business and segment notes in the linked annual filing for the issuer’s actual reporting segments.

Selected fundamentals

Annual reporting currency: USD. Financial amounts are in millions, except per-share figures and ratios.

Latest period 2025-12-31 · prior period 2024-12-31
Metric2025-12-312024-12-31Source filed
RevenueUSD 25,116mUSD 22,595m2026-02-11
Operating incomeUSD 4,889mUSD 3,689m2026-02-11
Net incomeUSD 3,246mUSD 2,993m2026-02-11
Diluted EPSUSD 8.40USD 7.762026-02-11
Operating cash flowUSD 5,044mUSD 4,242m2026-02-11
Capital expenditureUSD 761mUSD 755m2026-02-11
Free cash flowUSD 4,283mUSD 3,487m2026-02-11
Gross margin63.96%63.91%2026-02-11
Operating margin19.47%16.33%2026-02-11

FCF = operating cash flow − purchases of property, plant and equipment. Missing tags remain unavailable. Standardized cash-flow comparisons are particularly limited for financial businesses.

Inspect original metric provenance
{
  "revenue": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 25116000000,
    "accn": "0000310764-26-000010",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-11",
    "frame": "CY2025",
    "tag": "us-gaap:Revenues",
    "unit": "USD"
  },
  "netIncome": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 3246000000,
    "accn": "0000310764-26-000010",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-11",
    "frame": "CY2025",
    "tag": "us-gaap:NetIncomeLoss",
    "unit": "USD"
  },
  "grossProfit": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 16065000000,
    "accn": "0000310764-26-000010",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-11",
    "frame": "CY2025",
    "tag": "us-gaap:GrossProfit",
    "unit": "USD"
  },
  "operatingIncome": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 4889000000,
    "accn": "0000310764-26-000010",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-11",
    "frame": "CY2025",
    "tag": "us-gaap:OperatingIncomeLoss",
    "unit": "USD"
  },
  "eps": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 8.4,
    "accn": "0000310764-26-000010",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-11",
    "frame": "CY2025",
    "tag": "us-gaap:EarningsPerShareDiluted",
    "unit": "USD/shares"
  },
  "operatingCashFlow": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 5044000000,
    "accn": "0000310764-26-000010",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-11",
    "frame": "CY2025",
    "tag": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
    "unit": "USD"
  },
  "capex": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 761000000,
    "accn": "0000310764-26-000010",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-11",
    "frame": "CY2025",
    "tag": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment",
    "unit": "USD"
  },
  "totalAssets": {
    "end": "2025-12-31",
    "val": 47844000000,
    "accn": "0000310764-26-000010",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-11",
    "tag": "us-gaap:Assets",
    "unit": "USD"
  },
  "totalLiabilities": {
    "end": "2025-12-31",
    "val": 25424000000,
    "accn": "0000310764-26-000010",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-11",
    "tag": "us-gaap:Liabilities",
    "unit": "USD"
  },
  "currentAssets": {
    "end": "2025-12-31",
    "val": 14755000000,
    "accn": "0000310764-26-000010",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-11",
    "tag": "us-gaap:AssetsCurrent",
    "unit": "USD"
  },
  "currentLiabilities": {
    "end": "2025-12-31",
    "val": 7794000000,
    "accn": "0000310764-26-000010",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-11",
    "tag": "us-gaap:LiabilitiesCurrent",
    "unit": "USD"
  }
}

Annual earnings trend

Reported fiscal periods, not a live price chart.

Interactive chart loads in the browser. The full annual values are available below.

View all annual figures in a table
Period endRevenueNet incomeEPS
2025-12-31USD 25,116mUSD 3,246mUSD 8.40
2024-12-31USD 22,595mUSD 2,993mUSD 7.76
2023-12-31USD 20,498mUSD 3,165mUSD 8.25
2022-12-31USD 18,449mUSD 2,358mUSD 6.17

Valuation context

This release does not quote price-based multiples because it does not include synchronized market prices. A financial denominator must be paired with a clearly dated market value.

MeasureInterpretation
P/EPrice divided by EPS; identify annual, trailing or forward basis.
P/S & P/BMarket capitalization divided by sales or book equity.
EV / EBITDAEnterprise value and EBITDA need consistent definitions.
FCF yieldFree cash flow divided by dated market capitalization.

A sector median is descriptive, not a fair-value estimate. Explore sector context ↗

Selected filing notes

No filing note selected for this company in this release. Annual source filings remain available below.

Related research

Risks & what to monitor

Patent expiry, trial outcomes, reimbursement changes, litigation and acquisition integration.

Product concentration, research investment, utilization, reimbursement and cash generation.

Sources & dates